论文信息 - Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme - 字舞流文

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga | B. Biemond | A. A. van de Loosdrecht | G. Huls | M. Minnema | P. Wijermans | R. Schaafsma | A. Beeker | M. van Marwijk Kooy | O. de Weerdt | N. Veeger | M. Eefting | C. Alhan | M. Hoogendoorn | B. V. van Rees | J. Koedam | R. Brouwer | K. Jie | J. Wegman | S. L. Luykx-de Bakker | L. H. van der Helm | Ward J Libourel | F. Croon-de Boer | Monique C. Minnema | Pierre W. Wijermans | Bastiaan P. van Rees | Lieke H. van der Helm | Ward J. Libourel | Sylvia A. Luykx‐de Bakker | Nic J. G. M Veeger | Ward J. Libourel | S. L. Luykx‐de Bakker